Patents Assigned to Trustees of Boston University
  • Patent number: 10233498
    Abstract: The invention described herein relates to methods of treating emphysema and COPD with a GHK tripeptide. The invention further relates to methods of determining the state of the lungs using biomarkers described herein.
    Type: Grant
    Filed: January 19, 2017
    Date of Patent: March 19, 2019
    Assignees: TRUSTEES OF BOSTON UNIVERSITY, THE UNIVERSITY OF BRITISH COLUMBIA
    Inventors: Avrum Elliott Spira, Marc Lenburg, Joshua Campbell, Julie Erin Zeskind Gil, Dimitri Petchkovski, James Cameron Hogg
  • Publication number: 20190071472
    Abstract: The present invention is a DNA expression vector comprising: a toxP; a mutant toxO that blocks Fe-mediated regulation of gene expression; and a DNA sequence encoding a protein, wherein the toxP and the mutant toxO regulate expression of the DNA segment encoding the protein. It is preferred that DNA expression vectors of the present invention include DNA sequences encoding a signal peptide so that a protein expressed is attached to the signal peptide prior to processing. Novel proteins are produced off of the DNA expression vector of the present invention.
    Type: Application
    Filed: March 10, 2017
    Publication date: March 7, 2019
    Applicants: The Johns Hopkins University, Trustees of Boston University
    Inventors: William R. BISHAI, John R. MURPHY, Laurene CHEUNG, Shashank GUPTA, Cynthia K. BULLEN
  • Patent number: 10219581
    Abstract: An apparatus that assists foot movement includes a normally twisted plate configured to interact with the foot. The foot has a pronation axis, and the normally twisted plate is biased and configured to twist about a plate axis that substantially approximates the pronation axis in response to a load received from the foot during foot pronation. As the foot pronates, the plate twists to apply a non-linear force substantially about the plate axis.
    Type: Grant
    Filed: December 20, 2016
    Date of Patent: March 5, 2019
    Assignee: Trustees of Boston University
    Inventor: Kenneth G. Holt
  • Patent number: 10214763
    Abstract: A system and method for antibiotic susceptibility testing efficiently determines whether bacteria are alive or have been killed by antibiotic treatment. The antibiotic susceptibility testing device includes at least one reservoir into which a bacteria solution is introduced and a microfluidic channel connected to the reservoir, wherein the cross-sectional size of the microfluidic channel is selected to be comparable to the size of the bacterium to be tested. Furthermore, the electrical resistance or voltage signal across the microchannel is monitored as bacteria swim into and out of the channel. Alternatively, a small population of bacteria can be immobilized in the microchannel. The resistance or voltage signal fluctuates when the bacteria are alive and moving in and out of the channel or wiggling on the microchannel walls. If the bacteria are dead, they have limited motility and the signal fluctuations are significantly smaller.
    Type: Grant
    Filed: February 2, 2018
    Date of Patent: February 26, 2019
    Assignee: TRUSTEES OF BOSTON UNIVERSITY
    Inventors: Kamil Ekinci, Le Li, Chuanhua Duan, Vural Kara, Deborah Stearns-Kurosawa
  • Publication number: 20190054120
    Abstract: The technology described herein relates, at least in part, to compositions comprising and methods for isolating and enriching natural IgM-producing phagocytic B (NIMPAB) cells and methods of producing IgM antibodies using such cells, as well as uses of the antibodies produced by the methods for the prevention and treatment of diseases wherein immunotherapy with such natural IgM antibodies and their derivatives can be useful.
    Type: Application
    Filed: August 14, 2018
    Publication date: February 21, 2019
    Applicants: TRUSTEES OF BOSTON UNIVERSITY, BOSTON MEDICAL CENTER CORPORATION
    Inventors: Xuemei Zhong, Joyce Wong
  • Publication number: 20190054104
    Abstract: Provided herein are compositions and methods to improve treatment of chronic infections, and reduce, delay, or inhibit formation of biofilms, using specific combinations of aminoglycoside antibiotics and high, localized concentrations of one or more PMF stimulating compounds. These novel methods are easily adapted to clinical settings as toxicity and efficacy of the antibiotics and metabolites used have already been studied in vivo, and as dosing for both the antibiotics and metabolites are known. These approaches and therapeutic methods are also useful with non-metabolic chemicals that induce proton-motive force in bacteria.
    Type: Application
    Filed: August 27, 2018
    Publication date: February 21, 2019
    Applicant: TRUSTEES OF BOSTON UNIVERSITY
    Inventors: James J. Collins, Kyle R. Allison, Mark P. Brynildsen
  • Patent number: 10208312
    Abstract: The present invention provides nucleic acid molecules, DNA constructs, plasmids, and methods for post-transcriptional regulation of gene expression using RNA molecules to both repress and activate translation of an open reading frame. Repression of gene expression is achieved through the presence of a regulatory nucleic acid element (the cis-repressive RNA or crRNA) within the 5? untranslated region (5? UTR) of an mRNA molecule. The nucleic acid element forms a hairpin (stem/loop) structure through complementary base pairing. The hairpin blocks access to the mRNA transcript by the ribosome, thereby preventing translation. In particular, in embodiments of the invention designed to operate in prokaryotic cells, the stem of the hairpin secondary structure sequesters the ribosome binding site (RBS). In embodiments of the invention designed to operate in eukaryotic cells, the stem of the hairpin is positioned upstream of the start codon, anywhere within the 5? UTR of an mRNA.
    Type: Grant
    Filed: November 30, 2016
    Date of Patent: February 19, 2019
    Assignee: TRUSTEES OF BOSTON UNIVERSITY
    Inventors: James J. Collins, Farren J. Isaacs, Charles R. Cantor, Daniel J. Dwyer
  • Patent number: 10202457
    Abstract: Provided herein are novel compositions comprising anti-DEspR antibodies and fragments thereof derived from 6G8G7 and 7C5B2 anti-DEspR variant antibodies, including fully human, composite engineered human, humanized, monoclonal, and polyclonal anti-DEspR antibodies and fragments thereof, and methods of their use in a variety of therapeutic applications. The compositions comprising the anti-DEspR antibodies and fragments thereof described herein are useful in diagnostic and imaging methods, such as DEspR-targeted molecular imaging of angiogenesis, and for companion diagnostic and/or in vivo non-invasive imaging and/or assessments.
    Type: Grant
    Filed: August 24, 2016
    Date of Patent: February 12, 2019
    Assignee: TRUSTEES OF BOSTON UNIVERSITY
    Inventors: Nelson Ruiz-Opazo, Victoria L. M. Herrera, Francis Joseph Carr
  • Publication number: 20190040375
    Abstract: There are gluten-degrading enzymes found in Rothia species bacteria that are subtilisins that belonging to the S8A family of serine protease family. The Rothia sp. derived subtilisin-like enzymes have the conserved catalytic triad composed of a Ser, His, and Asp residues that is characteristic of the serine protease family. The Rothia subtilisin enzymes are potent at cleaving proline-containing proteins, cleaving the second peptide bond after proline in the XPX1 motif, where X is any amino acid, P is proline and X1 is a hydrophobic amino acid, e.g. the XPQ motif, where Q is glutamine. Embodiments herein provide isolated enzyme compositions and formulations comprising subtilisins gluten-degrading enzyme from a Rothia species bacteria. Also provided herein are methods of treatment of celiac disease or a related disorder, treatment of gluten-containing foodstuff, degrading and/or detoxifying gluten comprising the subtilisins gluten-degrading enzyme and/or compositions.
    Type: Application
    Filed: February 10, 2017
    Publication date: February 7, 2019
    Applicant: TRUSTEES OF BOSTON UNIVERSITY
    Inventors: Eva J. HELMERHORST, Guoxian WEI, Na TIAN, Detlef SCHUPPAN
  • Publication number: 20190040398
    Abstract: Provided herein are systems, methods and compositions for rendering cells or the expression of an effector protein sensitive to a predetermined condition. In one aspect, cells can be rendered dependent upon the presence of an environmental agent, e.g., an exogenous agent, without which the cell will default to expression of a death protein and be killed. In another aspect, cells can be rendered sensitive to the presence of a set of predetermined conditions such that cells will only grow when two or more necessary exogenous agents are supplied, and without either of which, the cells are killed. In this aspect, hybrid transcription factors provide a vast array of possible predetermined conditions.
    Type: Application
    Filed: September 30, 2016
    Publication date: February 7, 2019
    Applicant: TRUSTEES OF BOSTON UNIVERSITY
    Inventors: Tsz Yan Clement CHAN, James J. COLLINS, Jeong Wook LEE, Douglas Ewen CAMERON
  • Patent number: 10188795
    Abstract: Techniques are used for adaptation of drug-administration parameters that control insulin delivery in a blood glucose control system. One technique provides long-term adaptation of a nominal basal infusion rate, adapting to longer-term changes in a patient's needs due to growth, illness, hormonal fluctuations, physical activity, aging, etc. Another technique provides adaptation of priming dose size at mealtimes for overall better glycemic control and also adapting to longer-term changes in a patient's needs. Adaptation calculations use a receding-horizon window of recent values of the adapted parameter. Doses of a counter-regulatory agent (e.g., glucagon) may also be delivered in response to information about estimated accumulation of exogenously infused insulin (subcutaneously, intramuscularly, intraperitoneally, or intravenously) and/or the effect insulin might have on glucose levels (blood glucose concentration or interstitial fluid glucose concentration).
    Type: Grant
    Filed: December 15, 2016
    Date of Patent: January 29, 2019
    Assignees: Trustees of Boston University, The General Hospital Corporation
    Inventors: Firas El-Khatib, Edward Damiano, Steven J. Russell
  • Publication number: 20190025334
    Abstract: Disclosed herein are antibodies capable of specifically binding to tenofovir (TFV), a key small molecule drug for both the treatment and prevention of HIV, and a competitive lateral flow assay that uses these antibodies to monitor urine samples for the presence of the drug. The assay can be deployed as a point-of-care device for adherence monitoring.
    Type: Application
    Filed: July 20, 2018
    Publication date: January 24, 2019
    Applicant: TRUSTEES OF BOSTON UNIVERSITY
    Inventors: Catherine M. Klapperich, George Woodman Pratt IV, Andy Fan
  • Patent number: 10184888
    Abstract: A device for determining a refractive index may be provided. The device including at least one waveguide having a core and a cladding surrounding the core, the cladding being at least partly removed in at least one first longitudinal portion and the core including at least one fiber Bragg grating in at least one second longitudinal portion. A method for determining a refractive index or a pressure change in a fluid may also provided. The method may include at least one waveguide having a core and a cladding surrounding the core, the cladding being at least partly removed in at least one longitudinal portion. A method for producing such a device may also be provided.
    Type: Grant
    Filed: October 1, 2015
    Date of Patent: January 22, 2019
    Assignees: FRAUNHOFER-GESELLSCHAFT ZUR FÖRDERUNG DER ANGEWANDTEN FORSCHUNG E.V., TRUSTEES OF BOSTON UNIVERSITY
    Inventors: Wolfgang Schade, Jörg Burgmeier, Anna Lena Baumann, Björn Reinhard
  • Publication number: 20190008963
    Abstract: The invention provides oligonucleotide conjugates including a photolabile crosslinker attached to a cargo moiety, e.g., a therapeutic or diagnostic agent. The invention further provides reagents useful in the preparation of such conjugates and methods of their use.
    Type: Application
    Filed: March 1, 2017
    Publication date: January 10, 2019
    Applicants: Trustees of Boston University, Trustees of Boston University
    Inventors: Xue HAN, Richie E. KOHMAN, Susie S. CHA
  • Publication number: 20190010245
    Abstract: Described herein are compositions, methods, and systems for modulating Notch receptor activation. Aspects of the invention relate to synthetic proteins comprising at least a Notch NRR (Negative Regulatory Region)-binding scFV fused to a transmembrane domain. Another aspect of the invention relates to drug-dependent synthetic proteins. Constructs and engineered cells comprising the synthetic proteins are additionally described herein.
    Type: Application
    Filed: September 25, 2018
    Publication date: January 10, 2019
    Applicant: TRUSTEES OF BOSTON UNIVERSITY
    Inventor: John T. NGO
  • Patent number: 10174385
    Abstract: The technology described herein relates to assays and methods for the diagnosis, prognosis, and/or treatment of melanoma, e.g. relating to measuring the level of neurophilin-2 (NRP-2) mRNA expressed in melanoma cells. In some embodiments, the level of NRP-2 can be normalized to the level of Melan-A (MART) mRNA.
    Type: Grant
    Filed: December 19, 2014
    Date of Patent: January 8, 2019
    Assignee: TRUSTEES OF BOSTON UNIVERSITY
    Inventors: Rhoda M. Alani, Byungwoo Ryu
  • Patent number: 10175476
    Abstract: A system and method for correction of aberrations in a solid immersion microscopy system using a deformable mirror. A solid immersion lens is provided having a surface configured to make optical contact with a nearly planar surface of a substrate, an object to be imaged disposed on the opposite side of the substrate. A convex surface of the solid immersion lens faces an objective lens. A deformable mirror assembly, including a plurality of individually controllable actuators, receives light transmitted from the object. A control system controls in communication with the deformable mirror assembly provides individual actuation of each of the actuators of the deformable mirror to compensate or counteract the effects of aberrations.
    Type: Grant
    Filed: July 15, 2013
    Date of Patent: January 8, 2019
    Assignee: Trustees of Boston University
    Inventors: Bennett B. Goldberg, Thomas Bifano, Selim M. Unlu, Euan Ramsay, Fatih Hakan Koklu, Jerome Mertz, Yang Lu, Abdulkadir Yurt, Christopher Stockbridge
  • Publication number: 20180371421
    Abstract: Described herein are methods and compositions related to induced alveolar epithelial type 2 cells (iAEC2s), e.g., artificially-produced epithelial type 2 cells.
    Type: Application
    Filed: June 19, 2018
    Publication date: December 27, 2018
    Applicant: TRUSTEES OF BOSTON UNIVERSITY
    Inventors: Darrell N. Kotton, Anjali Jacob
  • Publication number: 20180369336
    Abstract: The technology described herein is directed to cellular cancer immunotherapies involving natural IgM producing phagocytic B (NIMPAB) cells and chemokines that attract the NIMPAB cells.
    Type: Application
    Filed: December 2, 2016
    Publication date: December 27, 2018
    Applicants: BOSTON MEDICAL CENTER CORPORATION, TRUSTEES OF BOSTON UNIVERSITY
    Inventors: Xuemei ZHONG, Tyrone M. PORTER, David C. SELDIN, Esther LANDESMAN, Hung VO, Joanna CHIU
  • Publication number: 20180353738
    Abstract: The inventions provided herein relate to tissue markers and uses thereof, e.g., to mark a target tissue site (e.g., a biopsy site in a breast tissue) or to produce a cell scaffold. The tissue markers described herein are designed to be resistant to fast migration (e.g., immediate migration after implantation through a needle track) and slow migration (e.g., over an extended period of time) upon implantation at a target tissue site (e.g., a biopsy site in a breast tissue), without using an adhesive. Additionally or alternatively, the tissue markers described herein can be readily detectable by at least one imaging modality, e.g., but not limited to magnetic resonance imaging, X-ray imaging, ultrasound imaging, or a combination thereof.
    Type: Application
    Filed: August 22, 2018
    Publication date: December 13, 2018
    Applicants: TRUSTEES OF BOSTON UNIVERSITY, BOSTON MEDICAL CENTER CORPORATION
    Inventors: Mark W. GRINSTAFF, Boris Nicolas BLOCH, Jonah KAPLAN